Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shrimp-Derived nanoparticles take on tough urinary tract infections

NCT ID NCT07482553

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This lab study tests whether chitosan nanoparticles—made from shrimp shells—can break down the sticky biofilms that protect E. coli bacteria in urinary tract infections. Researchers will collect bacteria from 60 patients and treat them with chitosan alone or with the antibiotic ciprofloxacin. They'll also coat urinary catheters with chitosan to see if it prevents biofilm buildup. The goal is to find new ways to fight hard-to-treat UTIs, especially those linked to catheters.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chitosan nanoparticles
What this could lead to
If successful, this could point toward a new way to prevent catheter-related infections and make antibiotics work better against stubborn UTIs.
What could go wrong
This is a small, early lab study, not yet tested in people. Results may not translate to real-world use, and chitosan's safety and effectiveness in patients are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include UTI patients attending Assiut University Hospitals. Urine samples will be collected aseptically for isolation of uropathogenic E. coli. Only patients meeting inclusion criteria and providing consent will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Patients (inpatients or outpatients) clinically diagnosed with urinary tract infection (UTI). 2\. Presence of significant bacteriuria in urine culture (≥10⁵ colony-forming units per milliliter (CFU/mL) for midstream urine, or as clinically indicated). 3\. Isolation of Escherichia coli as the sole or predominant pathogen from urine culture. 4\. Patients of any age and both sexes. 5. Patients who have not received antibiotic therapy within the previous 48-72 hours. Exclusion Criteria: * 1\. Patients who received systemic antibiotic therapy within the previous 48-72 hours prior to urine sample collection. 2\. Urine cultures showing insignificant bacteriuria (\<10⁵ CFU/mL for midstream urine, unless clinically justified). 3\. Polymicrobial growth in urine culture (mixed bacterial growth suggestive of contamination). 4\. Isolation of organisms other than Escherichia coli. 5. Improperly collected, leaking, or contaminated urine samples. 6. Patients unwilling to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biofilm formation by uropathogenic escherichia coli (UPEC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biofilm formation by uropathogenic escherichia coli (UPEC) Catheter-associated urinary tract infections (cautis) Urinary tract infections (UTIS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine, Assiut University, Microbiology and Immunity department

    Asyut, Assiut Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.